Abstract: As many as half of hepatocellular carcinomas are at advanced stage when first diagnosed, and advanced stage hepatocellular carcinoma lacks effective treatment which leads to a very poor prognosis. In recent years, Immune checkpoint inhibitors combined with anti-angiogenesis drugs has shown a high effective rate in the treatment of advanced hepatocellular carcinoma, which significantly prolongs the overall survival of the patients and also provides the possibility of the sequent radical surgery? In order to improve the long-term survival rate of the liver cancer patients and achieve the goal of increasing the 5-year overall survival rate by 15% according to "Healthy China 2030" plan, the Hepatobiliary and Pancreatic Disease Prevention and Control Committee of the Chinese Preventive Medicine Association and the Liver Cancer Committee of the Chinese Anti-Cancer Association have deep discussions on the key points of medical treatment of advanced hepatocellular carcinoma and a preliminary consensus was formed to guide clinical practice, standardize medical behavior, and promote disciplines.

Key words: Cancer, hepatocytes, Molecular targeted therapy, Hepatectomy, Immune checkpoint inhibitors, Translational therapy